Page 13 - Read Online

Costa-Guda. J Transl Genet Genom 2018;2:5 I http://dx.doi.org/10.20517/jtgg.2018.08 Page 7 of 8

25. DeLellis RA. Parathyroid tumors and related disorders. Mod Pathol 2011;24 Suppl 2:S78-93.
26. Agarwal SK, Simonds WF, Marx SJ. The parafibromin tumor suppressor protein interacts with actin-binding proteins actinin-2 and
actinin-3. Mol Cancer 2008;7:65.
27. Jo JH, Chung TM, Youn H, Yoo JY. Cytoplasmic parafibromin/hCdc73 targets and destabilizes p53 mRNA to control p53-mediated
apoptosis. Nat Commun 2014;5:5433.
28. Mosimann C, Hausmann G, Basler K. Parafibromin/Hyrax activates Wnt/Wg target gene transcription by direct association with beta-
catenin/Armadillo. Cell 2006;125:327-41.
29. James RG, Biechele TL, Conrad WH, Camp ND, Fass DM, Major MB, Sommer K, Yi X, Roberts BS, Cleary MA, Arthur WT, MacCoss
M, Rawlings DJ, Haggarty SJ, Moon RT. Bruton’s tyrosine kinase revealed as a negative regulator of Wnt-beta-catenin signaling. Sci
Signal 2009;2:ra25.
30. Takahashi A, Tsutsumi R, Kikuchi I, Obuse C, Saito Y, Seidi A, Karisch R, Fernandez M, Cho T, Ohnishi N, Rozenblatt-Rosen O,
Meyerson M, Neel BG, Hatakeyama M. SHP2 tyrosine phosphatase converts parafibromin/Cdc73 from a tumor suppressor to an
oncogenic driver. Mol Cell 2011;43:45-56.
31. Shtutman M, Zhurinsky J, Simcha I, Albanese C, D’Amico M, Pestell R, Ben-Ze’ev A. The cyclin D1 gene is a target of the beta-
catenin/LEF-1 pathway. Proc Natl Acad Sci U S A 1999;96:5522-7.
32. Tetsu O, McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999;398:422-6.
33. Woodard GE, Lin L, Zhang JH, Agarwal SK, Marx SJ, Simonds WF. Parafibromin, product of the hyperparathyroidism-jaw tumor
syndrome gene HRPT2, regulates cyclin D1/PRAD1 expression. Oncogene 2005;24:1272-6.
34. Lin L, Zhang JH, Panicker LM, Simonds WF. The parafibromin tumor suppressor protein inhibits cell proliferation by repression of the
c-myc proto-oncogene. Proc Natl Acad Sci U S A 2008;105:17420-5.
35. Juhlin CC, Haglund F, Villablanca A, Forsberg L, Sandelin K, Branstrom R, Larsson C, Hoog A. Loss of expression for the Wnt
pathway components adenomatous polyposis coli and glycogen synthase kinase 3-beta in parathyroid carcinomas. Int J Oncol
2009;34:481-92.
36. Svedlund J, Auren M, Sundstrom M, Dralle H, Akerstrom G, Bjorklund P, Westin G. Aberrant WNT/beta-catenin signaling in
parathyroid carcinoma. Mol Cancer 2010;9:294.
37. Iwata T, Mizusawa N, Taketani Y, Itakura M, Yoshimoto K. Parafibromin tumor suppressor enhances cell growth in the cells expressing
SV40 large T antigen. Oncogene 2007;26:6176-83.
38. Wang P, Bowl MR, Bender S, Peng J, Farber L, Chen J, Ali A, Zhang Z, Alberts AS, Thakker RV, Shilatifard A, Williams BO, Teh
BT. Parafibromin, a component of the human PAF complex, regulates growth factors and is required for embryonic development and
survival in adult mice. Mol Cell Biol 2008;28:2930-40.
39. Walls GV, Stevenson M, Lines KE, Newey PJ, Reed AAC, Bowl MR, Jeyabalan J, Harding B, Bradley KJ, Manek S, Chen J, Wang P,
Williams BO, Teh BT, Thakker RV. Mice deleted for cell division cycle 73 gene develop parathyroid and uterine tumours: model for the
hyperparathyroidism-jaw tumour syndrome. Oncogene 2017;36:4025-36.
40. Zhao L, Sun LH, Liu DM, He XY, Tao B, Ning G, Liu JM, Zhao HY. Copy number variation in CCND1 gene is implicated in the
pathogenesis of sporadic parathyroid carcinoma. World J Surg 2014;38:1730-7.
41. Pandya C, Uzilov AV, Bellizzi J, Lau CY, Moe AS, Strahl M, Hamou W, Newman LC, Fink MY, Antipin Y, Yu W, Stevenson M, Cavaco
BM, Teh BT, Thakker RV, Morreau H, Schadt EE, Sebra R, Li SD, Arnold A, Chen R. Genomic profiling reveals mutational landscape
in parathyroid carcinomas. JCI Insight 2017;2:e92061.
42. Vasef MA, Brynes RK, Sturm M, Bromley C, Robinson RA. Expression of cyclin D1 in parathyroid carcinomas, adenomas, and
hyperplasias: a paraffin immunohistochemical study. Mod Pathol 1999;12:412-6.
43. Imanishi Y, Hosokawa Y, Yoshimoto K, Schipani E, Mallya S, Papanikolaou A, Kifor O, Tokura T, Sablosky M, Ledgard F, Gronowicz
G, Wang TC, Schmidt EV, Hall C, Brown EM, Bronson R, Arnold A. Primary hyperparathyroidism caused by parathyroid-targeted
overexpression of cyclin D1 in transgenic mice. J Clin Invest 2001;107:1093-102.
44. Cryns VL, Thor A, Xu HJ, Hu SX, Wierman ME, Vickery AL, Jr., Benedict WF, Arnold A. Loss of the retinoblastoma tumor-suppressor
gene in parathyroid carcinoma. N Engl J Med 1994;330:757-61.
45. Cetani F, Pardi E, Viacava P, Pollina GD, Fanelli G, Picone A, Borsari S, Gazzerro E, Miccoli P, Berti P, Pinchera A, Marcocci C. A
reappraisal of the Rb1 gene abnormalities in the diagnosis of parathyroid cancer. Clin Endocrinol (Oxf) 2004;60:99-106.
46. Kim JK, Diehl JA. Nuclear cyclin D1: an oncogenic driver in human cancer. J Cell Physiol 2009;220:292-6.
47. Casimiro MC, Arnold A, Pestell RG. Kinase independent oncogenic cyclin D1. Aging (Albany NY) 2015;7:455-6.
48. Yu W, McPherson JR, Stevenson M, van Eijk R, Heng HL, Newey P, Gan A, Ruano D, Huang D, Poon SL, Ong CK, van Wezel T,
Cavaco B, Rozen SG, Tan P, Teh BT, Thakker RV, Morreau H. Whole-exome sequencing studies of parathyroid carcinomas reveal
novel PRUNE2 mutations, distinctive mutational spectra related to APOBEC-catalyzed DNA mutagenesis and mutational enrichment in
kinases associated with cell migration and invasion. J Clin Endocrinol Metab 2015;100:E360-4.
49. Sulaiman L, Haglund F, Hashemi J, Obara T, Nordenstrom J, Larsson C, Juhlin CC. Genome-wide and locus specific alterations in
CDC73/HRPT2-mutated parathyroid tumors. PLoS One 2012;7:e46325.
50. Friedman E, Bale AE, Marx SJ, Norton JA, Arnold A, Tu T, Aurbach GD, Spiegel AM. Genetic abnormalities in sporadic parathyroid
adenomas. J Clin Endocrinol Metab 1990;71:293-7.
51. Yoshimoto K, Iwahana H, Fukuda A, Sano T, Katsuragi K, Kinoshita M, Saito S, Itakura M. ras mutations in endocrine tumors:
mutation detection by polymerase chain reaction-single strand conformation polymorphism. Jpn J Cancer Res 1992;83:1057-62.
52. Cryns VL, Rubio MP, Thor AD, Louis DN, Arnold A. p53 abnormalities in human parathyroid carcinoma. J Clin Endocrinol Metab